SCHEMBL15437867

SCHEMBL15437867

O=C1C(Cl)=C(c2ccccc2)C(=O)N1c1cccc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD51 Q06609 5/20 0.70
▸ MGLL Q99685 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.49
▸ GAA P10253 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ HTT P42858 3/20 0.49
▸ TSHR P16473 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PKM P14618 2/20 0.49
▸ BCL2A1 Q16548 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ CASP6 P55212 1/20 0.46
▸ ATM Q13315 2/20 0.44
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15437791 0.92 RAD51 (0.58) RAD51MGLLALDH1A1GAAMAPT
SCHEMBL15437908 0.88 RAD51 (0.71) RAD51MGLLALDH1A1GAAMAPT
SCHEMBL15437833 0.84 RAD51 (0.51) RAD51MGLLALDH1A1GAAMAPT
SCHEMBL15437731 0.83 RAD51 (0.69) RAD51MGLLALDH1A1MAPTTSHR
SCHEMBL17201930 0.83 RAD51 (1.00) RAD51ALDH1A1MAPTBCL2A1KMT2A
SCHEMBL11649332 0.82 MGLL (0.64) MGLLALDH1A1GAAMAPTHTT
SCHEMBL15437773 0.79 MEN1 (0.53) RAD51MGLLGAAMAPTHTT
SCHEMBL2553055 0.75 KDM4E (0.68) MGLLALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL4528994 0.74 MGLL (0.54) RAD51MGLLALDH1A1GAAMAPT
SCHEMBL14777408 0.74 NR1H2 (0.53) RAD51MGLLALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US claimed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US claimed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US claimed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 RAD51 1883/4885MGLL 4191/4885ALDH1A1 3334/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 RAD51 2803/4885MGLL 4069/4885ALDH1A1 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback